Andrew Technologies has announced it has received FDA clearance for the commercially manufactured version of its HydraSolve lipoplasty system, according to a news release.
The company said it has successfully completed design verification and validation of the device versus the previously cleared prototype device.
HydraSolve is described by Andrew Technologies as a "novel liposuction device based on the same patented Tissue Liquefaction Technology that was launched in 2003 by Alcon as the AquaLase liquefaction device for precision cataract surgery." It combines natural saline solution with low levels of pressure and temperature to liquefy targeted fat tissue.
Andrew Technologies said it will complete the manufacturing of the initial launch devices and will begin commercialization with a selective launch to pre-identified expert plastic surgeons in the United States in early 2013. The company intends to expand the launch nationally by mid-2013 and begin rest of world distribution in 2014.
Andrew Technologies is headquartered in Orange County, Calif.
Related Articles on FDA Clearances:
Lutronic Receives FDA Clearance for Phototherapy System
Halt Medical Receives FDA Clearance for System to Treat Uterine Fibroids
aap Implantate AG Receives FDA Clearance for Trauma Plating System